Lumakras — CareFirst (Caremark)
KRAS G12C-mutated recurrent, advanced or metastatic non-small cell lung cancer (NSCLC)
Initial criteria
- Treatment of KRAS G12C‑mutated recurrent, advanced or metastatic NSCLC
- Member has received at least one prior systemic therapy
- Requested medication will be used as a single agent
Reauthorization criteria
- No evidence of unacceptable toxicity
- No disease progression while on current regimen
Approval duration
12 months